Clinical Trial Update: Study of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation Therapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating nivolumab after neoadjuvant therapy and concurrent chemoradiation for stage III non-small-cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Stage III Non-small-cell Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING